WealthTrust Axiom LLC boosted its stake in Novartis AG (NYSE:NVS) by 0.0% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 18,258 shares of the company’s stock after buying an additional 3 shares during the period. WealthTrust Axiom LLC’s holdings in Novartis AG were worth $1,506,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of NVS. Private Trust Co. NA increased its stake in shares of Novartis AG by 1.7% in the second quarter. Private Trust Co. NA now owns 2,899 shares of the company’s stock valued at $239,000 after buying an additional 48 shares in the last quarter. Carroll Financial Associates Inc. increased its stake in shares of Novartis AG by 1.1% in the second quarter. Carroll Financial Associates Inc. now owns 4,597 shares of the company’s stock valued at $379,000 after buying an additional 50 shares in the last quarter. Sigma Planning Corp increased its stake in shares of Novartis AG by 0.9% in the second quarter. Sigma Planning Corp now owns 6,545 shares of the company’s stock valued at $540,000 after buying an additional 59 shares in the last quarter. Albert D Mason Inc. increased its stake in shares of Novartis AG by 0.3% in the second quarter. Albert D Mason Inc. now owns 19,099 shares of the company’s stock valued at $1,576,000 after buying an additional 64 shares in the last quarter. Finally, Capital Analysts LLC increased its stake in shares of Novartis AG by 3.5% in the second quarter. Capital Analysts LLC now owns 2,084 shares of the company’s stock valued at $172,000 after buying an additional 70 shares in the last quarter. Institutional investors own 9.78% of the company’s stock.

Shares of Novartis AG (NYSE:NVS) traded up 0.63% during trading on Thursday, reaching $82.03. 1,594,450 shares of the company’s stock were exchanged. The stock has a market capitalization of $195.33 billion, a PE ratio of 29.29 and a beta of 0.58. The company’s 50-day moving average is $80.75 and its 200 day moving average is $78.38. Novartis AG has a 52 week low of $69.90 and a 52 week high of $95.11.

Novartis AG (NYSE:NVS) last issued its quarterly earnings data on Tuesday, July 19th. The company reported $1.23 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.18 by $0.05. Novartis AG had a net margin of 13.84% and a return on equity of 15.33%. The company earned $12.47 billion during the quarter, compared to the consensus estimate of $12.33 billion. During the same quarter last year, the company earned $1.25 earnings per share. On average, analysts forecast that Novartis AG will post $4.72 earnings per share for the current year.

Several analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of Novartis AG from a “sell” rating to a “hold” rating in a research report on Wednesday, June 15th. Chardan Capital assumed coverage on shares of Novartis AG in a research report on Tuesday. They set a “buy” rating and a $95.00 price objective for the company. JPMorgan Chase & Co. restated a “buy” rating on shares of Novartis AG in a research report on Tuesday, July 19th. Bank of America Corp. restated a “hold” rating on shares of Novartis AG in a research report on Tuesday, July 12th. Finally, TheStreet upgraded shares of Novartis AG from a “hold” rating to a “buy” rating in a research report on Friday, June 24th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $91.83.

Novartis AG Company Profile

Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.

5 Day Chart for NYSE:NVS

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.